Pathology - Myasthenia Gravis

Pathology - Myasthenia Gravis
Pathophysiology 
At the neuromuscular junction, an antibody-mediated response is the source of the pathophysiology of MG.
Though they can potentially target muscle fibers or receptor tyrosine kinases unique to a particular muscle, antibodies are most frequently directed against acetylcholine receptors on the postsynaptic membrane. The action potential is transmitted and depolarized when ACh binds to its postsynaptic receptor in patients without MG; however, this reaction is attenuated by the antibodies generated in MG. Patients who are active tend to develop weaker with time and are more prone to weariness. Individuals may have diplopia, eyelid droop, dysphagia, dysarthria, or respiratory discomfort in addition to ocular muscle weakness. This is more common towards the end of the day. Since diaphragmatic involvement can be lethal, respiratory stabilization is the primary focus of patient care for MG patients. To raise the quantity of acetylcholine at the motor end plate, acetylcholinesterase inhibitors, such as pyridostigmine, are employed. In circumstances where symptoms are life-threatening, intravenous immunoglobulin (IVIG) or plasma exchange may be able to temporarily relieve them. For cases like this one, surgical thymoma resection is a curative treatment when thymoma on imaging is documented.